期刊
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
卷 323, 期 21, 页码 2160-2169出版社
AMER MEDICAL ASSOC
DOI: 10.1001/jama.2020.6348
关键词
-
资金
- National Science Foundation (National Research Program 74 Smarter Health Care grant) [407440_167359]
- Swiss National Science Foundation (SNF) [407440_167359] Funding Source: Swiss National Science Foundation (SNF)
Key PointsQuestionDoes antibiotic treatment with C-reactive protein (CRP)-guided duration or fixed 7-day duration, compared with fixed 14-day duration, provide noninferior clinical failure rates in patients with uncomplicated gram-negative bacteremia? FindingsIn this randomized clinical trial that included 504 adults with uncomplicated gram-negative bacteremia, 30-day clinical failure occurred in 2.4% of patients assigned to receive CRP-guided antibiotic treatment duration, 6.6% assigned to 7-day treatment, and 5.5% assigned to 14-day treatment. The differences between CRP-guided treatment and 7-day treatment compared with 14-day treatment met the noninferiority criterion of 10%, but adherence to the CRP strategy or planned follow-up did not occur in 23% of patients. MeaningCRP-guided treatment and 7-day treatment were noninferior to 14-day treatment in patients with uncomplicated gram-negative bacteremia, but interpretation is limited by the large noninferiority margin compared with the low observed event rate and lower adherence in the CRP-guided group. ImportanceAntibiotic overuse drives antibiotic resistance. Gram-negative bacteremia is a common infection that results in substantial antibiotic use. ObjectiveTo compare the clinical effectiveness of C-reactive protein (CRP)-guided, 7-day, and 14-day antibiotic durations 30, 60, and 90 days after treatment initiation. Design, Setting, and ParticipantsMulticenter, noninferiority, point-of-care randomized clinical trial including adults hospitalized with gram-negative bacteremia conducted in 3 Swiss tertiary care hospitals between April 2017 and May 2019, with follow-up until August 2019. Patients and physicians were blinded between randomization and antibiotic discontinuation. Adults (aged >= 18 years) were eligible for randomization on day 5 (1 d) of microbiologically efficacious therapy for fermenting, gram-negative bacteria in blood culture(s) if they were afebrile for 24 hours without evidence for complicated infection (eg, abscess) or severe immunosuppression. InterventionRandomization in a 1:1:1 ratio to an individualized CRP-guided antibiotic treatment duration (discontinuation once CRP declined by 75% from peak; n=170), fixed 7-day treatment duration (n=169), or fixed 14-day treatment duration (n=165). Main Outcomes and MeasuresThe primary outcome was the clinical failure rate at day 30, defined as the presence of at least 1 of the following, with a non-inferiority margin of 10%: recurrent bacteremia, local suppurative complication, distant complication (growth of the same organism causing the initial bacteremia), restarting gram-negative-directed antibiotic therapy due to clinical worsening suspected to be due to the initial organism, or death due to any cause. Secondary outcomes included the clinical failure rate on day 90 of follow-up. ResultsAmong 504 patients randomized (median [interquartile range] age, 79 [68-86] years; 306 of 503 [61%] were women), 493 (98%) completed 30-day follow-up and 448 (89%) completed 90-day follow-up. Median antibiotic duration in the CRP group was 7 (interquartile range, 6-10; range, 5-28) days; 34 of the 164 patients (21%) who completed the 30-day follow-up had protocol violations related to treatment assignment. The primary outcome occurred in 4 of 164 (2.4%) patients in the CRP group, 11 of 166 (6.6%) in the 7-day group, and 9 of 163 (5.5%) in the 14-day group (difference in CRP vs 14-day group, -3.1% [1-sided 97.5% CI, -infinity to 1.1]; P<.001; difference in 7-day vs 14-day group, 1.1% [1-sided 97.5% CI, - to 6.3]; P<.001). By day 90, clinical failure occurred in 10 of 143 patients (7.0%) in the CRP group, 16 of 151 (10.6%) in the 7-day group, and 16 of 153 (10.5%) in the 14-day group. Conclusions and RelevanceAmong adults with uncomplicated gram-negative bacteremia, 30-day rates of clinical failure for CRP-guided antibiotic treatment duration and fixed 7-day treatment were noninferior to fixed 14-day treatment. However, interpretation is limited by the large noninferiority margin compared with the low observed event rate, as well as low adherence and wide range of treatment durations in the CRP-guided group. Trial RegistrationClinicalTrials.gov Identifier: NCT03101072 This randomized trial compares the effects of C-reactive protein (CRP)-guided antibiotic duration (discontinuation once CRP declined by 75% of peak value) vs fixed 7- vs 14-day durations on 30-day clinical failure rate among patients with gram-negative bacteremia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据